DNA Biomed Solns (DNA) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of DNA Biomed Solns ILS 0.23, price ILS 0.99, upside -76.8%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DNA Biomed Solns for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 0.5650 ILA – 1.86 ILA · fair‑value band 0.2100 ILA – 0.2500 ILA · the 0.9910 ILA price screens above the 0.2300 ILA fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow DNA Biomed Solns in your weekly email
Every Wednesday you see whether DNA Biomed Solns is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children.
Show more
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.
Stock analysis
DNA Biomed Solns (DNA) currently trades at 0.9910 ILA, while our model-based Fair Value estimate is 0.2300 ILA, implying the stock looks roughly 330.8% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.4500 ILA per share, and 0 of the 19 models we run sit above the 0.9910 ILA price.
Bear case: the Asset-Based group reads lowest at 0.0800 ILA, and 19 of the 19 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.2100 ILA (bear) to 0.2500 ILA (bull), the price of 0.9910 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
DNA Biomed Solns reported revenue of 306K ILS in FY2024 versus 0 ILS in FY2020. Reported net income was 22.1M ILS in FY2024.
Key figures
Market cap 921M ILA · Net margin 169% · Return on equity 0.5% · Return on assets (EBIT) −13.8% · Operating margin −376% · Revenue (TTM) 306K ILA · EPS growth (YoY) +635% · Free cash flow 1.6M ILA.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
For context, the median of 10 Consumer Cyclical peers we cover trades at −29% fair-value upside, at −77%, DNA screens richer than that median.
Fair Value models
Bear 0.2100 ILAFair Value 0.2300 ILABull 0.2500 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
+0.0%
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
’08
’09
’22
’23
’24
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−4.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.9%
Dividend (yield on the price)0.0%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +31.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Lodging · 168 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−77% · Bottom 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets−1% · Bottom 25%
Net margin (TTM)169% · Top 25%
Growth and dividend
Revenue growth0% · Below median
Balance sheet
Debt / equity0.18× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)0· sector 23
PAST (return on equity)2· sector 12
HEALTH (low debt)91· sector 88
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DNA Biomed Solns (DNA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.2300 ILA versus a price of 0.9910 ILA, about −77% upside (overvalued).
What is the fair value of DNA?
Our model-based fair value for DNA Biomed Solns is 0.2300 ILA (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.9910 ILA.
What is the quality score of DNA?
DNA Biomed Solns has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DNA Biomed Solns (DNA)?
Our model-based price target is the fair value of 0.2300 ILA (as of Sep 24, 2026) from 19 valuation models. Cautious scenario 0.2100 ILA, optimistic scenario 0.2500 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the DNA Biomed Solns stock forecast for 2026?
Our models put fair value at 0.2300 ILA, about −77% upside versus a price of 0.9910 ILA (overvalued). Cautious scenario 0.2100 ILA, optimistic scenario 0.2500 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of DNA Biomed Solns (DNA)?
DNA Biomed Solns reported trailing-twelve-month revenue of about 306K ILS (latest available figure, as of Sep 24, 2026).
What growth is priced into DNA Biomed Solns (DNA)?
For today's price to be fair in a discounted-cash-flow model, DNA Biomed Solns would have to grow free cash flow by +34.0 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 15 years revenue grew -8.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DNA use?
Our models discount DNA Biomed Solns at 13.1 %: a base by market capitalisation (small), country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DNA Biomed Solns that is +34.0 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has DNA Biomed Solns (DNA) delivered so far?
Over the past 15 years revenue at DNA Biomed Solns grew -8.5 % a year. The price currently implies +34.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DNA Biomed Solns (DNA) growing?
The median revenue growth in the sector is +8.4 % a year. That is the yardstick for the growth priced into DNA Biomed Solns (+34.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DNA Biomed Solns (DNA)?
The free-cash-flow yield on the price is 1.32 %: that much free cash flow DNA Biomed Solns produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DNA Biomed Solns (DNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DNA Biomed Solns it is 0.2300 ILA per share (as of Sep 24, 2026), against a price of 0.9910 ILA. It is the blended result of 19 valuation models (cash flow, earnings, asset, dividend).
Is DNA Biomed Solns stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DNA trades above its calculated fair value: price 0.9910 ILA, fair value 0.2300 ILA, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DNA?
No. The price is what the market pays today (0.9910 ILA); the fair value is what the company's own numbers justify (0.2300 ILA). For DNA Biomed Solns the two are 0.7610 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is DNA Biomed Solns worth?
The market values DNA Biomed Solns at about 921M ILA (market capitalisation, as of Sep 24, 2026). Per share that is 0.9910 ILA; our models calculate a fair value of 0.2300 ILA per share.
What do the bullish and bearish scenarios say about DNA?
Our models span a range for DNA Biomed Solns: cautious scenario 0.2100 ILA, base 0.2300 ILA, optimistic 0.2500 ILA per share (as of Sep 24, 2026, price 0.9910 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DNA Biomed Solns (DNA)?
Balance-sheet figures for DNA Biomed Solns (as of Sep 24, 2026): return on equity 0.5%, debt of 0.18 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
Which stocks are comparable to DNA Biomed Solns?
From the same area (Consumer Cyclical) we also value Marriott International, Inc, Hilton Worldwide Holdings, InterContinental Hotels Group, Hyatt Hotels Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DNA Biomed Solns stock attractive at the current price?
The data as of Sep 24, 2026: price 0.9910 ILA, calculated fair value 0.2300 ILA (−77%), Quality Score 59/100, from 19 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DNA calculated?
We run DNA Biomed Solns through 19 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2300 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. DNA Biomed Solns itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DNA Biomed Solns (DNA)?
The closing price on Sep 22, 2026 was 0.9910 ILA. Our model-based fair value is 0.2300 ILA, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DNA Biomed Solns right now?
The price sits above even our optimistic bull case (0.2500 ILA). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of DNA Biomed Solns
How large is the market capitalisation of DNA Biomed Solns (DNA)?
The market capitalisation of DNA Biomed Solns is 921M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of DNA Biomed Solns (DNA)?
The net margin of DNA Biomed Solns is 169% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DNA Biomed Solns (DNA)?
The return on equity (ROE) of DNA Biomed Solns is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DNA Biomed Solns (DNA)?
On an EBIT basis the return on assets of DNA Biomed Solns is −13.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DNA Biomed Solns (DNA)?
The operating margin of DNA Biomed Solns is −376% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at DNA Biomed Solns (DNA)?
Earnings per share at DNA Biomed Solns are growing +635% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does DNA Biomed Solns (DNA) hold?
DNA Biomed Solns holds more cash than debt, 68.3M ILA net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch DNA Biomed Solns in the live analysis
One click puts DNA Biomed Solns on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
